公司概述
IM Cannabis Corp. operates as a specialized entity within the healthcare sector, specifically functioning in the drug manufacturers - specialty & generic industry. The company's core business activities involve the breeding, cultivation, and supply of medical cannabis products, offering dried flowers and various cannabis extracts under the IMC, BLKMT, WAGNERS, and LOT420 brands to serve medical patients in Israel and Germany. As of the latest data, the company holds a market capitalization of $2.21 million and reports annual revenue of $54.73 million, while its employee count is listed as unavailable. These financial dimensions indicate that the company operates with a relatively small market capitalization relative to its reported revenue stream, suggesting a valuation that does not fully reflect its current top-line scale or implying potential inefficiencies in capitalization relative to operational output.
财务健康
The financial performance of IM Cannabis Corp. over the trailing twelve months shows revenue of $54.73 million, a net income loss of $11,319,000, and an EBITDA of -$4,559,000. The significant disparity between the positive revenue of $54.73 million and the substantial net loss of $11,319,000 reveals a cost structure where operating expenses and cost of goods sold are consuming more than twenty percent of the top line, resulting in a profit margin of -20.7%. Furthermore, the operating margin stands at -31.4%, which indicates that operational inefficiencies or high fixed costs are eroding profitability even before interest and taxes. The company's free cash flow is -$431,875, meaning the firm is consuming cash rather than generating it, which limits its financial flexibility for organic expansion or capital expenditures without external financing. On the balance sheet, the company holds $2.73 million in cash against $16.27 million in debt, resulting in a negative debt-to-equity metric where the ratio is listed as N/A due to the equity position, indicating a highly leveraged state. The current ratio is 0.67, signaling that current assets are insufficient to cover current liabilities without liquidating non-current assets or securing new financing. Additionally, the return on assets is -10.9% and the return on equity is N/A, metrics that collectively reveal that management is currently destroying value rather than generating returns on the capital base employed.
估值评估
Valuation multiples for IM Cannabis Corp. present a complex picture, with a trailing P/E ratio listed as N/A due to the net loss and a forward P/E of -0.27. The negative forward P/E implies that the market expects earnings to remain negative or for the company to continue operating at a loss in the near term. The price-to-book ratio is -0.78, which indicates that the market is pricing the company at less than the book value, often a sign of market skepticism regarding future growth potential or recognition of the high risk associated with the negative equity. Alternative valuation metrics such as the price-to-sales ratio of 0.04 and an EV/EBITDA of -3.48 suggest that the stock is priced at a very low multiple relative to its sales, reflecting the speculative nature of the investment. Regarding trading range, the 52-week high is $7.12 and the 52-week low is $0.29; without a specific current price provided in the facts, the valuation context relies on these extremes to define the asset's volatility band. The stock exhibits a beta of 2.27, indicating that the company's price volatility is more than twice that of the broader market, making it a highly sensitive asset to market swings.
Growth & Income
In terms of growth and income, the company reported a revenue growth of 17.6% year-over-year, while earnings growth is listed as N/A due to the ongoing net losses. The divergence between positive revenue growth and negative earnings growth implies that top-line expansion has not yet translated into bottom-line profitability, a common characteristic in capital-intensive biotech or cannabis sectors still in a development phase. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any available cash flow is theoretically retained for operational needs rather than distributed. The overall growth and income profile is characterized by expanding sales volumes offset by structural losses, with no current income stream for investors in the form of dividends.